Vaxcyte, Inc. $PCVX Position Lessened by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA trimmed its position in Vaxcyte, Inc. (NASDAQ:PCVX) by 21.5% in the third quarter, HoldingsChannel.com reports. The firm owned 545,434 shares of the company’s stock after selling 149,285 shares during the period. Pictet Asset Management Holding SA’s holdings in Vaxcyte were worth $31,035,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Covestor Ltd raised its stake in shares of Vaxcyte by 31.1% in the 3rd quarter. Covestor Ltd now owns 939 shares of the company’s stock valued at $53,000 after buying an additional 223 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Vaxcyte during the 3rd quarter worth about $1,270,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in shares of Vaxcyte during the 3rd quarter valued at about $1,650,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Vaxcyte by 18.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 27,151 shares of the company’s stock valued at $1,539,000 after acquiring an additional 4,170 shares in the last quarter. Finally, BG Investment Services LLC acquired a new stake in shares of Vaxcyte during the 3rd quarter valued at about $1,075,000. 96.78% of the stock is owned by institutional investors.

Insider Buying and Selling at Vaxcyte

In other news, CAO Elvia Cowan sold 19,000 shares of the firm’s stock in a transaction dated Monday, October 5th. The shares were sold at an average price of $86.74, for a total value of $1,648,060.00. Following the transaction, the chief accounting officer owned 27,860 shares of the company’s stock, valued at approximately $2,416,576.40. This trade represents a 40.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Jim Wassil sold 18,000 shares of the business’s stock in a transaction that occurred on Monday, October 5th. The stock was sold at an average price of $86.74, for a total transaction of $1,561,320.00. Following the sale, the executive vice president directly owned 145,435 shares of the company’s stock, valued at approximately $12,615,031.90. This trade represents a 11.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 50,692 shares of company stock worth $4,032,875 in the last ninety days. 3.30% of the stock is currently owned by insiders.

Vaxcyte Stock Down 1.7%

Vaxcyte stock opened at $66.36 on Wednesday. Vaxcyte, Inc. has a 12-month low of $42.40 and a 12-month high of $90.75. The stock has a 50-day simple moving average of $61.98 and a 200 day simple moving average of $57.47. The company has a quick ratio of 4.56, a current ratio of 4.56 and a debt-to-equity ratio of 0.04.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, November 4th. The company reported ($1.99) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.11) by $0.12. During the same quarter last year, the business posted ($1.56) earnings per share. On average, equities research analysts predict that Vaxcyte, Inc. will post -7.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on PCVX. Guggenheim upped their target price on shares of Vaxcyte from $116.00 to $125.00 and gave the company a “buy” rating in a research note on Monday, October 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research note on Friday, October 2nd. Bank of America decreased their price objective on Vaxcyte from $133.00 to $130.00 and set a “buy” rating on the stock in a report on Monday, September 28th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $120.00 price objective on shares of Vaxcyte in a research note on Monday, October 12th. Finally, Zacks Research upgraded Vaxcyte from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 12th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $110.50.

Vaxcyte Profile

Vaxcyte, Inc. is a clinical-stage biotechnology company developing vaccines to prevent bacterial infectious diseases. Its research focuses on conjugate vaccines, which link bacterial sugars to carrier proteins to help generate an immune response. The company’s pipeline includes VAX-24 and VAX-31, investigational pneumococcal vaccines designed to protect against a broad range of strains, as well as VAX-A1, a candidate targeting Group A Streptococcus. Vaxcyte has no approved commercial vaccines; its programs remain under development.